Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;32(8):745-58.
doi: 10.1007/s40273-014-0164-8.

Economic Evaluations of Gastroesophageal Reflux Disease Medical Management

Affiliations
Free PMC article
Review

Economic Evaluations of Gastroesophageal Reflux Disease Medical Management

Andrew J Gawron et al. Pharmacoeconomics. .
Free PMC article

Abstract

Background: Gastroesophageal reflux disease (GERD) contributes to substantial medication use and costs worldwide. Economic evaluations provide insight into the value of healthcare, taking into account cost, quality, and benefits of particular treatments.

Objectives: Our objectives were to systematically review the existing literature to identify economic evaluations of GERD management strategies, to assess the scientific quality of these reports, and to summarize the economic outcomes of these evaluations.

Methods: We identified economic evaluations and cost studies of GERD management strategies by searching PubMed and the UK NHS Economic Evaluation Database via the Cochrane Library. Searching was restricted to articles in English-language journals from July 2003 to July 2013. Cost-identification articles were excluded from the final analysis.

Results: Eighteen articles were included in the final analysis; 61 % of these met all criteria for quality reporting. Overall, proton pump inhibitor (PPI) therapy was preferred (most effective and least costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high Helicobacter pylori prevalence (>40 %). Initial empiric PPI therapy (vs. initial endoscopy stratification or H. pylori testing) is likely the most cost-effective initial strategy for patients with typical GERD symptoms. Surgery may be cost effective in patients with chronic GERD symptoms at time horizons of 3-10 years. Endoscopic anti-reflux procedures were not cost effective based on available data.

Conclusions: Further economic evaluations should adhere to standard reporting measures of cost estimates and outcomes, and should attempt to account for and compare the large heterogeneity of patient phenotypes and treatment effects seen with anti-reflux therapies.

Conflict of interest statement

Declaration of Interests

Drs. Gawron and French have no outside interests to declare.

Dr. Pandolfino has served as a consultant for Given Imaging.

Dr. Howden has served as a consultant and speaker for Takeda, Otsuka, Ironwood and Forest and as a speaker for GlaxoSmithKline International.

Figures

Figure 1
Figure 1. Review search strategy and results
1One additional article was included via expert opinion on manuscript review that was not identified via the literature search

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Feedback